Loading...
•
Sep 30, 2025
Strata Critical Medical Q3 2025 Earnings Report
Strata Critical Medical reported a wider net loss in Q3 2025, despite strong revenue growth and improved margins.
Key Takeaways
Strata Critical Medical saw revenue jump 36.7% year-over-year to $49.3 million in Q3 2025. However, net loss widened to $9.7 million due to increased legal and investment-related expenses. Flight profit and margins improved, and the company posted record Medical Segment Adjusted EBITDA.
Revenue rose 36.7% YoY to $49.3 million, driven by Air and Ground Logistics growth.
Net loss widened to $9.7 million, largely due to legal reserves and realized investment losses.
Adjusted EBITDA surged to $4.2 million, up from $67K a year ago.
Medical Segment Adjusted EBITDA reached $7.6 million, with a margin of 15.3%.
Forward Guidance
Strata raised its 2025 revenue guidance and reaffirmed Adjusted EBITDA expectations, supported by strong organic growth and the integration of Keystone Perfusion.
Positive Outlook
- 2025 revenue guidance raised to $185–195 million.
- Adjusted EBITDA guidance reaffirmed at $13–14 million.
- Strong customer adoption of new services post-Keystone acquisition.
- Market share gains despite industry seasonal softness.
- Continued growth in organ transplant procedures using NRP technology.
Challenges Ahead
- Net loss increased year-over-year due to legal and investment losses.
- Operating loss remained at $5.6 million despite revenue growth.
- Realized $5.2 million loss from sale of short-term investments.
- Legal reserves contributed significantly to higher expenses.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...